They must clearly distinguish their products from gray-market manufacturers caught in the FDA’s crosshairs.

Consumers are treating health and wellness as essential spending even in a tough economy. Social media and wellness culture are fueling demand for supplements, healthier food, and longevity products. At the same time, misinformation and pressure to stay healthy are increasing.

Amazon should resist trying to disrupt US healthcare and instead focus on delivering a consumer-friendly care experience.

Healthcare membership buyers tend to skew younger, but a new GoodRx offering could tap a broader market of consumers losing coverage while still needing routine care.

As more consumers turn to AI for health advice, embedded clinical tools aim to build trust where confidence remains low.

Amazon aims to turn GLP-1 demand into a funnel for One Medical, though limiting new prescriptions to members softens the competitive threat to other telehealth players.

Consumers may be drawn to unregulated peptide products for now, but long-term brand success in this space will depend on transparency and clear education.

Consumers turn to search engines first for answers to health-related questions, even as social, video, and AI tools gain ground. Meanwhile, streaming TV is reshaping healthcare ad reach. Digital drives health-related action—but trust gaps shadow every channel.

Novo drops court fights to secure GLP-1 distribution, which will drive other telehealth brands to weigh pharma deals against legal risk.

Steady telehealth use among patients supports many market players, but winners will pair Rx access with user experience, AI, and caring providers.

Hims & Hers’ former partner plans to continue copycat GLP-1 sales even as FDA investigations and patent lawsuits raise the risks.

Rising legal and regulatory scrutiny of compounded weight loss drugs suggests branded pharma ties are the safer avenue for telehealth players to sell their copycat GLP-1s.

The Eucalyptus deal deepens global reach as diversification beyond compounded GLP-1s in the US becomes urgent.

Novo’s lawsuit and regulator warnings signal a crackdown on compounded GLP-1s across telehealth.

Novo’s Big Game spot can help reinforce the Wegovy pill’s credibility against copycat compounded versions.

Weight loss hype pushed Lilly well ahead of Novo, yet Novo’s early pill win signals a turn toward more affordable, convenient obesity treatments.

Pharma and health brands return to the Super Bowl, ditching drug pitches for brand storytelling campaigns.

Rising demand clashes with high costs, no insurance coverage, and doctors’ reluctance to validate outside results.

Wisp acquires TBD Health to scale nationwide, adding clinics and diagnostics to meet rising demand for virtual care among women.

More than a third of patients will switch doctors who don’t modernize the experience.